Divalproex Sodium Tablet, Film Coated, Extended Release
Product Images NDC 0378-0472

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 0378-0472). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Divalproex Sodium Extended-release Tablets 250 mg Bottle Label (Image 01)

This is a description of a medication containing divalproex sodium, used to treat seizures and bipolar disorder. The tablets are extended-release and the usual dosage is specified in accompanying prescribing information. The medication guide should be given to each patient, and the tablets must be kept in a tightly closed, child-resistant container at room temperature. The manufacturer is Mylan Pharmaceuticals Inc. The text also contains a unique NDC code for the medication.*

FDA Label Image

Divalproex Sodium Extended-release Tablets 500 mg Bottle Label (Image 02)

FDA Label Image

Divalproex Sodium Structural Formula (Image 03)

FDA Label Image

Figure 1: Proportion Of Patients (x Axis) Whose Percentage Reduction From Baseline In Complex Partial Seizure Rates Was At Least As Great As That Indicated On The Y Axis In The Adjunctive Therapy Study (Image 04)

The text appears to be a graph displaying % Reduction in CP$ Rate versus % of Patients along with indicators of improvement, no change or worsening. No further information is provided.*

FDA Label Image

Figure 2: Proportion Of Patients (x Axis) Whose Percentage Reduction From Baseline In Complex Partial Seizure Rates Was At Least As Great As That Indicated On The Y Axis In The Monotherapy Study (Image 05)

This seems to be a graph showing the distribution of patients and their response to different doses of a drug called Divalroex Sodium. It looks like the graph is showing the percentage of patients who experienced certain responses to different doses of the drug, ranging from low dose to high dose. The responses seem to be classified as "No Change", "Delayed Release", and "High Dose" with varying percentages for each category. Overall, it looks like the graph is displaying the effectiveness of different doses of Divalroex Sodium on patients.*

FDA Label Image

Figure 3. Mean Reduction In 4-week Migraine Headache Rates (Image 06)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.